Prime Medicine won an arbitration ruling against Beam Therapeutics, determining that Prime’s work on its gene-editing therapy for alpha-1 antitrypsin deficiency (AATD) did not violate a 2019 agreement intended to prevent competitive overlap. The decision clears the way, at least for now, for Prime to proceed toward a clinical program planned to start this quarter. The ruling is a direct legal inflection point for two adjacent gene-editing companies spun out of the same lab, and it reduces near-term development risk tied to IP or agreement interpretation. Beam’s position is weakened by the arbitration outcome. The dispute’s resolution also highlights how deal and collaboration structures can constrain platform execution in gene editing, where multiple groups often target overlapping biology with different payload or editing designs.